Document Detail


An overview of the pharmacokinetics, efficacy and safety of liraglutide.
MedLine Citation:
PMID:  22245694     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
OBJECTIVE: Incretin-based therapies, including glucagon-like peptide 1 (GLP-1) receptor agonists, are the latest addition to the range of available medications for the management of patients with type 2 diabetes. The GLP-1 analog liraglutide has been approved for use in Europe and the US for over a year and has undergone evaluation in several pharmacokinetic/pharmacodynamics studies and in an extensive phase 3 clinical program. The aim of this review is to assess the pharmacokinetics, efficacy and safety of the phase 3 data. METHODS: Data are presented from the pharmacokinetics/pharmacodynamics studies of liraglutide and from nine published phase 3 studies, including the six Liraglutide Effect and Action in Diabetes (LEAD) studies. RESULTS: Liraglutide is effective at improving indices of glycemic control, and has a good tolerability and safety profile. Beneficial effects on weight (mean reduction of 1-3.4kg) and blood pressure (systolic blood pressure decreased by 2.1-6.7mmHg) are also observed. CONCLUSION: Liraglutide is an effective and well tolerated option for the treatment of type 2 diabetes.
Authors:
Bruce Bode
Related Documents :
6991384 - Psychometric evaluation of performance in diabetes mellitus.
2053214 - Gauging the likelihood of cavitation from short-pulse, low-duty cycle diagnostic ultras...
21240364 - Manifestation of adaptive changes during combined development of postinfarction remodel...
9364344 - Maturity-onset diabetes of the young (mody): three case reports and new perspectives.
2900484 - Long-term replicability of eeg spectra and auditory evoked potentials in schizophrenic ...
8425674 - Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-1-13
Journal Detail:
Title:  Diabetes research and clinical practice     Volume:  -     ISSN:  1872-8227     ISO Abbreviation:  -     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2012-1-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8508335     Medline TA:  Diabetes Res Clin Pract     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012. Published by Elsevier Ireland Ltd.
Affiliation:
Atlanta Diabetes Associates, 77 Collier Rd, Suite 2080, Atlanta, GA 30309, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Metformin alters the expression profiles of microRNAs in human pancreatic cancer cells.
Next Document:  Sex differences in the relationship between socioeconomic status and metabolic syndrome: The Korean ...